Study Objective: To validate the ApneaLINK (AL) as an accurate tool for determining the presence of obstructive sleep apnea (OSA) in an at-risk sleep clinic population in a home test environment. Methods: Consecutive participants referred with the suspicion of OSA were evaluated in the home with the AL portable monitor (AL Home), followed by simultaneous data collection with diagnostic polysomnography (PSG) and AL in the sleep laboratory (AL Lab). Prevalence, sensitivity, specifi city, and ROC curves were calculated for PSG vs. AL Lab, PSG vs. AL Home, and AL Lab vs. AL Home test. Pearson correlations and Bland-Altman plots were constructed. Results: Fifty-three (55% female) participants completed the entire study. The mean age of the population was 45.1 ± 11.3 years, and body mass index was 35.9 ± 9.1 kg/m 2 . The prevalence of an apnea hypopnea index (AHI) ≥ 15 in the cohort was 35.9%. The results demonstrated a high sensitivity and specificity of the AL respiratory disturbance index (RDI-AL) compared with the AHI from the PSG. The AL Lab had the highest sensitivity and specificity at RDI-AL values ≥ 20 events/h (sensitivity 100%, specificity 92.5%). The AL Home was most sensitive and specific at an RDI-AL ≥ 20 events/h (sensitivity 76.9%, specificity 92.5%). The Pearson correlations for PSG vs. AL Lab and PSG vs. AL Home were ρ = 0.88 and ρ = 0.82, respectively. The BlandAltman Plots demonstrated good agreement between the methodologies. Conclusion: The AL home test is an accurate alternative to PSG in sleep clinic populations at risk for moderate and severe OSA. Trial Registration: clinicaltrials.gov ID: NCT00354614. Keywords: Obstructive sleep apnea, portable monitoring, diagnosis Citation: Oktay B; Rice TB; Atwood CW; Passero M; Gupta N; Givelber R; Drumheller OJ; Houck P; Gordon N; Strollo PJ. Evaluation of a single-channel portable monitor for the diagnosis of obstructive sleep apnea.

If MS accompanies OSAS, which is a cardiovascular risk factor by itself, treatment indications of CPAP should be reevaluated. Thus, if OSA patients meet the criteria of MS even though they do not have obvious DM, HT and hyperlipidemia, initiating CPAP treatment at lower AHI levels may contribute to the prevention and development of cardiovascular disease.

The aim of this study was to establish cardiac damage related to nocturnal ischemia using heart type fatty acid binding protein (h-fabp), which reaches detectable levels in plasma after being released from myocytes in case of ischemia in obstructive sleep apnea syndrome (OSAS) patients without coronary artery disease (CAD). Fifty patients diagnosed with OSAS in our sleep laboratory with polysomnographic analysis (PSG), who did not have any previous history of cardiac disease and in whom CAD was ruled out with myocardium perfusion scintigraphy, were included in the study. Control group comprised 19 volunteers without history of cardiac disease and risk factors in whom OSAS was excluded with PSG analysis. Blood samples were drawn from the patients to examine h-fabp, creatine kinase (CK), creatine kinase-MB (CK-MB), aspartate aminotransferase (AST), troponin I levels before and after sleep. No significant difference was found in CK, CK-MB, AST, Troponin I, and h-fabp levels before and after sleep in patient and control groups (p > 0.05). No significant difference was found between groups in terms of CK, CK-MB, AST, and Troponin I levels before and after sleep, while a significant difference was found between them with regard to h-fabp levels before (p = 0.006) and after sleep (p = 0.022). When arithmetical mean of the fabp levels before and after sleep was taken in the patient group, it was found that mean value of h-fabp was associated with the desaturated period in sleep which was under 80% (p = 0.04). H-fabp seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in OSAS patients before development of disease that can be detected by imaging methods. Further studies are required to investigate the relation between the value of h-fabp and the development of cardiac dysfunction in the long term.

Sleep disordered breathing (SDB) represents a major public health problem. We investigated the risk of SDB and associated factors in the Turkish adult population. We collected data by an interviewer‐administered questionnaire in a nationwide representative sample of 5021 adults (2598 women, 2423 men) with a mean age of 40.7 years (SD:15.1) in 2010. High risk of SDB was defined as the positive response to at least two of the three categories in the Berlin questionnaire (BQ). High risk of SDB was found in 13.7% (men: 11.1%, women: 20.2%). High risk of SDB prevalence was not significantly different between the genders in the analysis stratified for BMI categories. Female gender, older age, lower level of education and smoking in the past were associated with high risk of SDB in the logistic regression analysis models adjusting for age and gender. After the adjustment for age, gender, smoking, BMI and educational status, high risk of SDB, and BQ Category 2 score were associated with previous hospitalization and cardiovascular diseases. Risk due to BQ Category 1 and BQ Category 2 was more than additive in the models for hypertension and heart disease for the age groups 45–65 years and 65 years and over. Higher prevalence of SDB and obesity among women in our population should be addressed in further studies. Association between high risk of SDB and cardiovascular diseases, if confirmed, indicates the public health importance of screening for SDB symptoms.

ÖZET Bronkoskopik inceleme ile tanı alan endobronşiyal tüberküloz olgusu Endobronşiyal tüberküloz (EBTB), trakeobronşiyal ağacın tüberküloz ile infeksiyonu olarak tanımlanır ve erişkin popülas Endobronchial tuberculosis is defined as tuberculosis infection of tracheobronchial tree and it is not seen often in adult po